Leading global law firm Baker McKenzie has advised the international pharmaceutical laboratory Servier on the acquisition of Agios Pharmaceuticals’s oncology business. The transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties.
In line with its strategic ambition to become a recognized and innovative actor in the field of oncology, this acquisition will enable the Servier group to strengthen its product porfolio and its drug development pipeline. It will also significantly reinforce the French laboratory’s presence in the US where the group has been operating since 2018.
Founded in 2008 in Massachusetts, Agios Pharmaceuticals specializes in research and development of drugs for the treatment of hematologic malignancies, solid tumours and rare genetic diseases thanks to its scientific leadership in the field of cellular metabolism.
Laboratoires Servier’s internal team was made up of Benoit Chéron, Corporate Law Director, Matthieu Guerineau, Director of the Contracts department, Jawad Fassi-Fehri, Senior Corporate Law Legal Adviser, Mayalen Lacabarats, Head of the Contratcs department division.
Laboratoires Servier were advised by Baker McKenzie with a team in Paris led by Stéphane Davin, partner, and Elsa Lesclide, M&A associate and Léna Sersiron, partner, on competition law aspects and a team in the US led by Michael DeFranco with assistance from Veleka-Peeples Dyer on FDA law aspects, as well as Christian Burholt, Partner, and Katrin Kurz, Associate, in Berlin on competition matters.
Back in 2018, Baker McKenzie assisted the Servier group in the framework of its acquisition of Shire’s global oncology business.